Haleon (LON:HLN) Reaches New 52-Week High – Still a Buy?

Haleon plc (LON:HLN) reached a new 52-week high during trading on Saturday . The company traded as high as GBX 402.30 ($5.06) and last traded at GBX 395.30 ($4.97), with a volume of 76461156 shares trading hands. The stock had previously closed at GBX 382.40 ($4.81).

Haleon Trading Up 3.4 %

The company has a quick ratio of 0.93, a current ratio of 0.84 and a debt-to-equity ratio of 53.36. The company has a market cap of £35.68 billion, a price-to-earnings ratio of 33.25, a PEG ratio of 1.49 and a beta of 0.19. The firm has a 50 day moving average price of GBX 379.73 and a two-hundred day moving average price of GBX 379.15.

Haleon (LON:HLN) last posted its quarterly earnings data on Friday, February 28th. The company reported GBX 15.80 ($0.20) earnings per share for the quarter. Haleon had a net margin of 9.66% and a return on equity of 6.54%. As a group, equities analysts forecast that Haleon plc will post 19.5033282 earnings per share for the current year.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s portfolio spans five global categories including Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health and Digestive Health and other.